Exit remaining shares

Brad Holland

Brad has over 20 years experience in the Australian and US equities and options markets. Brad specialises in equities and options for capital growth, income generation and capital protection. He also specialises in finding opportunities in small to medium cap stocks. Brad holds RG146 - Securities & Managed Investments and Accredited Derivatives Adviser Level 2 qualifications.



February 1, 2022



ACL.AX | High Conviction Report

With the number of covid-19 cases in NSW and around the country starting to drop off, the ACL share price is beginning to retreat. So it is time to sell the remaining shares and lock in profits before earnings are reported in the next few weeks.

The company has been a significant beneficiary of the surge in covid testing, but the current elevated testing numbers are unlikely to continue as the omicron strain fades and more Rapid Antigen Tests (RAT) become available.

Trade Action

Sell 1,000 ACL at the current market price of $5.07

Closed position result

Number of shares purchased: 2,000

Initial Buy price: $4.40

Average sale price: $5.51 (shares sold in two parcels 1,000 at $5.95 and 1,000 shares at $5.07)

Profit on closed position : $2,220.00

This is general advice only. MF & Co Asset Management has not considered your personal financial needs, objectives or current situation. This information is not an offer, solicitation, or a recommendation for any financial product unless expressly stated. You should seek professional investment advice before making any investment decision.